The use of cytoprotectants in the treatment of gynecological malignancies

References

• Cancer facts and figures. American Cancer Society; 2005
   Google Scholar
• Schoenike SE, Dana WJ. Ifosfamide and mesna. Clin Pharm 1990;9:179–191
   PubMedGoogle Scholar
• Hasinoff BB. The iron(III) and copper(II) complexes of adriamycin promote the hydrolysis of the cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)- propane). Agents Actions 1990;29:374–381
   PubMedGoogle Scholar
• Romanol FL, Bannister RG. Histochemistry: Localized areas of high alkaline phosphatase activity in endothelium of arteries. Nature 1962;195:611–612
   Google Scholar
• Millar JL, McElwain TJ, Clutterbuck RD, et al. The modification of melphalan toxicity in tumor bearing mice by s-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR 2721). Am J Clin Oncol 1982;5:321–328
   PubMed Web of Science ®Google Scholar
• Yuhas JM. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Res 1980;40:1519–1524
   PubMed Web of Science ®Google Scholar
• Scheef W, Klein HO, Brock N, et al. Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results. Cancer Treat Rep 1979;63:501–505
   PubMedGoogle Scholar
• Fukuoka M, Negoro S, Masuda N, et al. Placebo-controlled double-blind comparative study on the pre-ventive efficacy of mesna against ifosfamide-induced urinary disorders. J Cancer Res Clin Oncol 1991;117: 473–478
   PubMed Web of Science ®Google Scholar
• Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 1992;10: 117–127
   Google Scholar
• Yuhas JM, Storer JB. Differential chemoprotection of normal and malignant tissues. J Natl Cancer inst 1969;42:331–335
   PubMed Web of Science ®Google Scholar
• Schuchter LM. Current role of protective agents in cancer treatment. Oncology (Huntingt) 1997;11:505-512,515-506; discussion 517–508
   Google Scholar
• Glover D, Glick JH, Weiler C, et al. Phase I trials of WR-2721 and cis-platinum. Int J Radiat Oncol Biol Phys 198410:1781-1784
   PubMed Web of Science ®Google Scholar
• Glover D, Grabelsky S, Fox K, et al. Clinical trials of WR-2721 and cis-platinum. Int J Radiat Oncol Biol Phys 1989;16:1201–1204
   PubMed Web of Science ®Google Scholar
• Glover D, Glick JH, Weiler C, et al. WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncol 1987;5:574–578
   PubMed Web of Science ®Google Scholar
• Glover D, Glick JH, Weiler C, et al. Phase I/II trials of WR-2721 and cis-platinum. Int J Radiat Oncol Biol Phys 1986;12:1509–1512
   PubMed Web of Science ®Google Scholar
• Glover D, Glick JH, Weiler C, et al. WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial. J Clin Oncol 1986;4: 584–588
   PubMed Web of Science ®Google Scholar
• Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide- induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996;14:2101–2112
   PubMed Web of Science ®Google Scholar
• McGuire WP, Hoskins WJ, Brady MF, et al. Cyclopho-sphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1–6
   PubMed Web of Science ®Google Scholar
• Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000;92:699–708
   PubMed Web of Science ®Google Scholar
• Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194–3200
   PubMed Web of Science ®Google Scholar
• Lorusso D, Ferrandina G, Greggi S, et al. Phase III multicenter randomized trial of amifostine as cytoprotec-tant in first-line chemotherapy in ovarian cancer patients. Ann Oncol 2003;14:1086–1093
   PubMed Web of Science ®Google Scholar
• De Vos FY, Bos AM, Schaapveld M, et al. A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinoma. Gynecol Oncol 2005;97:60–67
   Google Scholar
• Gold MA, Walker JL, Berek JS, et al. Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: results of a multicenter phase III trial in patients with advanced gynecologic malignancies. Gynecol Oncol 2003;90:325–330
   PubMed Web of Science ®Google Scholar
• Omura GA. Chemotherapy for cervix cancer. Semin Oncol 1994;21:54–62
   Google Scholar
• Cannistra SA, Niloff JM. Cancer of the uterine cervix. N Engl J Med 1996;334:1030–1038
   PubMed Web of Science ®Google Scholar
• Pignata S, De Vivo R, Ricchi P, et al. Chemotherapy in squamous cell carcinoma of the cervix uteri: present
   Google Scholar
• Gallardo D, Mohar A, Calderillo G, et al. Cisplatin, radiation, and amifostine in carcinoma of the uterine
   Google Scholar
• Budd GT, Ganapathi R, Adelstein DJ, et al. Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors. Cancer 1997;80:1134–1140
   PubMed Web of Science ®Google Scholar
• Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000;18: 3339–3345
   PubMed Web of Science ®Google Scholar
• Ben-Josef E, Han S, Tobi M, et al. Intrarectal application of amifostine for the prevention of radiation-induced rectal injury. Semin Radiat Oncol 2002;12:81–85
   PubMed Web of Science ®Google Scholar
• Liu T, Liu Y, He S, et al. Use of radiation with or without WR-2721 in advanced rectal cancer. Cancer 1992;69: 2820–2825
   PubMed Web of Science ®Google Scholar
• Athanassiou H, Antonadou D, Coliarakis N, et al. Protective effect of amifostine during fractionated radio-therapy in patients with pelvic carcinomas: Results of a randomized trial. Int J Radiat Oncol Biol Phys 2003;56:1154–1160
   PubMed Web of Science ®Google Scholar
• Hensley ML, Schuchter LM, Lindley C, et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999;17:3333–3355
   PubMed Web of Science ®Google Scholar
• Schuchter LM, Luginbuhl WE, Meropol NJ. The current status of toxicity protectants in cancer therapy. Semin Oncol 1992;19:742–751
   PubMed Web of Science ®Google Scholar
• Schuchter LM, Hensley ML, Meropol NJ, et al. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2002;20:2895–2903
   Google Scholar